Your browser is no longer supported. Please, upgrade your browser.
RZLT [NASD]
Rezolute, Inc.
Index- P/E- EPS (ttm)-3.02 Insider Own24.90% Shs Outstand8.51M Perf Week2.31%
Market Cap65.50M Forward P/E- EPS next Y-2.64 Insider Trans- Shs Float6.18M Perf Month-6.95%
Income-25.10M PEG- EPS next Q-0.69 Inst Own36.60% Short Float0.23% Perf Quarter-32.00%
Sales- P/S- EPS this Y22.90% Inst Trans104.29% Short Ratio0.30 Perf Half Y-56.50%
Book/sh2.53 P/B1.75 EPS next Y19.80% ROA-65.60% Target Price20.40 Perf Year-70.98%
Cash/sh2.52 P/C1.76 EPS next 5Y- ROE-89.20% 52W Range4.01 - 17.47 Perf YTD-7.53%
Dividend- P/FCF- EPS past 5Y42.20% ROI- 52W High-74.70% Beta3.55
Dividend %- Quick Ratio14.80 Sales past 5Y- Gross Margin- 52W Low10.22% ATR0.39
Employees26 Current Ratio14.80 Sales Q/Q- Oper. Margin- RSI (14)41.82 Volatility8.29% 8.25%
OptionableNo Debt/Eq0.65 EPS Q/Q-49.20% Profit Margin- Rel Volume1.36 Prev Close4.61
ShortableYes LT Debt/Eq0.65 Earnings- Payout- Avg Volume47.36K Price4.42
Recom1.60 SMA20-5.61% SMA50-11.94% SMA200-45.33% Volume64,468 Change-4.12%
Sep-08-21Initiated ROTH Capital Buy $21
May-27-21Initiated Oppenheimer Outperform $25
May-25-21Initiated H.C. Wainwright Buy $21
Nov-12-21 04:05PM  
Oct-19-21 12:14PM  
Oct-13-21 08:10AM  
Oct-12-21 04:05PM  
Sep-22-21 04:05PM  
Sep-15-21 04:56PM  
Sep-09-21 04:05PM  
Sep-07-21 04:05PM  
Aug-10-21 07:00AM  
Aug-03-21 07:00AM  
Jun-28-21 07:00AM  
Jun-24-21 09:01PM  
Jun-03-21 05:35AM  
May-31-21 10:17AM  
May-27-21 07:00AM  
May-20-21 07:00AM  
May-18-21 07:00AM  
May-17-21 04:05PM  
07:00AM  
May-04-21 08:00AM  
Apr-19-21 08:00AM  
Mar-22-21 08:00AM  
Mar-08-21 08:00AM  
Mar-02-21 05:16PM  
Feb-10-21 04:05PM  
Jan-12-21 08:30AM  
Jan-11-21 07:56AM  
Dec-28-20 04:05PM  
Dec-03-20 08:00AM  
Nov-19-20 08:00AM  
Nov-05-20 08:00AM  
Oct-09-20 08:30AM  
Sep-10-20 08:00AM  
Jul-27-20 08:00AM  
Jun-15-20 08:30AM  
May-28-20 08:30AM  
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.